Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

athenahealth's More Disruption Please Conference 2014

Summary

Related Content

HHS Exclusion Becomes a Two-Headed Monster Featuring CMS and OIG

Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar

FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review

DOJ Fraud Division and HHS-OIG Announce Policy to Coordinate on Voluntary Self-Disclosures in Healthcare Fraud Matters

Genentech and Biocon Settle Pertuzumab Biosimilar BPCIA Litigation

Teva and Samsung Bioepis Add Up to Six Biosimilar Candidates to Partnership

FDA Finalizes Q&A Guidance on Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

Fresenius Acquires Remaining 45% Stake in mAbxience for Up to €750 Million

Goodwin Advises Disc Medicine on $450 Million Upsized Public Offering

Goodwin Advises Hansoh on Collaboration Agreement With Roche for $400 Million Upfront and Up To $15 Billion in Milestone Payments

Goodwin Advises Syndicate of Existing Investors on Microbiotica's £36 Million Series C Financing

Goodwin Advises Lakefront Biotherapeutics on Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Goodwin Advises Frazier Life Sciences Acquisition Corp. II on Its $75 Million Initial Public Offering

Goodwin Advises the Placement Agents on $160 Million PIPE Financing

Goodwin Advises City Therapeutics on Pricing of $200 Million Upsized Initial Public Offering

Goodwin Advises OMass Therapeutics on $310 Million Series C

Life Sciences

Technology